Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.69 |
| ▸ | MEN1 | O00255 | 5/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23116634 | 0.88 | MEN1 (0.72) | KDM4EMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL28344541 | 0.88 | CYP2D6 (0.64) | KDM4EMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL28334395 | 0.88 | CYP2D6 (0.64) | KDM4EMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL28344534 | 0.88 | CYP2D6 (0.64) | KDM4EMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL28344589 | 0.88 | CYP2D6 (0.64) | KDM4EMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL10845107 | 0.86 | CYP2D6 (0.71) | KDM4EMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL10845287 | 0.86 | CYP2D6 (0.71) | KDM4EMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL4179880 | 0.86 | CYP2D6 (0.71) | KDM4EMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL10845109 | 0.86 | CYP2D6 (0.71) | KDM4EMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL8317770 | 0.86 | CYP2D6 (0.71) | KDM4EMEN1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0891187-B1 | USE OF DERIVATIVES OF TETRAHYDRO-BETA-CARBOLINES AS ANTIMETASTATIC AGENTS | HOFFMANN LA ROCHE (CH) | 2002-01-30 | — | — | EP | claimed |
| US-6069150-A | METALLOPROTRINASE INHIBITOR | F. HOFFMAN-LA ROCHE AG (CH) | 2000-05-30 | — | — | US | claimed |
| EP-0891187-A1 | USE OF DERIVATIVES OF TETRAHYDRO-BETA-CARBOLINES AS ANTIMETASTATIC AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 1999-01-20 | — | — | EP | claimed |
| WO-1997037658-A1 | USE OF DERIVATIVES OF TETRAHYDRO-BETA-CARBOLINES AS ANTIMETASTATIC AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 1997-10-16 | — | — | WO | claimed |
| US-20240043422-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | US | disclosed |
| US-11613538-B2 | Method of inhibiting or reducing a viral infection | PTC THERAPEUTICS, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| EP-2434891-B9 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20200317668-A1 | METHOD OF INHIBITING OR REDUCING A CORONAVIRIDAE VIRUS INFECTION | PTC THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| EP-3718405-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC Therapeutics, Inc. (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-2434891-B1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS INC (US) | 2020-07-22 | — | — | EP | disclosed |
| CN-110799652-A | Differentiated stem cells and agents for treating cancer | 米纳瓦生物技术公司 | 2020-02-14 | — | — | CN | disclosed |
| US-20190194188-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2010138695-A1 | METHODS FOR TREATING NEUROFIBROMATOSIS | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138659-A1 | METHODS FOR TREATING BRAIN TUMORS | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138706-A1 | METHODS FOR TREATING BREAST CANCER | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138685-A1 | METHODS FOR TREATING PROSTATE CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| EP-0891187-B1 | USE OF DERIVATIVES OF TETRAHYDRO-BETA-CARBOLINES AS ANTIMETASTATIC AGENTS | HOFFMANN LA ROCHE (CH) | 2002-01-30 | — | — | EP | disclosed |
| US-6069150-A | METALLOPROTRINASE INHIBITOR | F. HOFFMAN-LA ROCHE AG (CH) | 2000-05-30 | — | — | US | disclosed |
| EP-0891187-A1 | USE OF DERIVATIVES OF TETRAHYDRO-BETA-CARBOLINES AS ANTIMETASTATIC AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 1999-01-20 | — | — | EP | disclosed |
| WO-1997037658-A1 | USE OF DERIVATIVES OF TETRAHYDRO-BETA-CARBOLINES AS ANTIMETASTATIC AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 1997-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043422-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | KDM4E 2344/4885MEN1 2704/4885KMT2A 2631/4885 |
| US-20190194188-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | KDM4E 2347/4885MEN1 2681/4885KMT2A 2639/4885 |
| US-20200317668-A1 | METHOD OF INHIBITING OR REDUCING A CORONAVIRIDAE VIRUS INFECTION | SARS1, POLRMT, EIF2AK2 | KDM4E 3113/4885MEN1 4724/4885KMT2A 3745/4885 |
| US-11613538-B2 | Method of inhibiting or reducing a viral infection | SARS1, EIF2AK2, POLRMT | KDM4E 3202/4885MEN1 4541/4885KMT2A 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.